Literature DB >> 16054105

Should chloroquine be laid to rest?

Hagai Ginsburg1.   

Abstract

Chloroquine (CQ) has been the front line antimalarial drug due to its efficacy, low cost and scanty side effects, until resistance has evolved. Although its use has been officially discontinued in most malaria-affected countries, it is still widely used. Practical and pharmacological considerations indicate that it could be still used in semi-immune adults and that more efficient treatment protocols could be devised to treat even patients infected with CQ-resistant parasite strains. Since its antimalarial activity is pleiotropic, drug resistance may be due to different mechanisms, each amenable to reversal by drug combination.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16054105     DOI: 10.1016/j.actatropica.2005.06.021

Source DB:  PubMed          Journal:  Acta Trop        ISSN: 0001-706X            Impact factor:   3.112


  14 in total

Review 1.  Know your enemy: understanding the role of PfCRT in drug resistance could lead to new antimalarial tactics.

Authors:  Robert L Summers; Megan N Nash; Rowena E Martin
Journal:  Cell Mol Life Sci       Date:  2012-06       Impact factor: 9.261

2.  A chloroquine-like molecule designed to reverse resistance in Plasmodium falciparum.

Authors:  Steven J Burgess; Audrey Selzer; Jane Xu Kelly; Martin J Smilkstein; Michael K Riscoe; David H Peyton
Journal:  J Med Chem       Date:  2006-09-07       Impact factor: 7.446

Review 3.  Artemisinin-based combination therapies: a vital tool in efforts to eliminate malaria.

Authors:  Richard T Eastman; David A Fidock
Journal:  Nat Rev Microbiol       Date:  2009-11-02       Impact factor: 60.633

4.  Synthesis and Study of the Antimalarial Cardamom Peroxide.

Authors:  Xirui Hu; Pharath Lim; Rick M Fairhurst; Thomas J Maimone
Journal:  Tetrahedron       Date:  2018-03-26       Impact factor: 2.457

5.  Pharmacokinetics, pharmacodynamics, and allometric scaling of chloroquine in a murine malaria model.

Authors:  Brioni R Moore; Madhu Page-Sharp; Jillian R Stoney; Kenneth F Ilett; Jeffrey D Jago; Kevin T Batty
Journal:  Antimicrob Agents Chemother       Date:  2011-06-06       Impact factor: 5.191

6.  Chloroquine susceptibility and reversibility in a Plasmodium falciparum genetic cross.

Authors:  Jigar J Patel; Drew Thacker; John C Tan; Perri Pleeter; Lisa Checkley; Joseph M Gonzales; Bingbing Deng; Paul D Roepe; Roland A Cooper; Michael T Ferdig
Journal:  Mol Microbiol       Date:  2010-09-29       Impact factor: 3.501

7.  Reversal agent and linker variants of reversed chloroquines: activities against Plasmodium falciparum.

Authors:  Simeon Andrews; Steven J Burgess; Deborah Skaalrud; Jane Xu Kelly; David H Peyton
Journal:  J Med Chem       Date:  2010-01-28       Impact factor: 7.446

8.  Population pharmacokinetics of chloroquine and sulfadoxine and treatment response in children with malaria: suggestions for an improved dose regimen.

Authors:  Celestino Obua; Urban Hellgren; Muhammed Ntale; Lars L Gustafsson; Jasper W Ogwal-Okeng; Toufigh Gordi; Markus Jerling
Journal:  Br J Clin Pharmacol       Date:  2008-02-20       Impact factor: 4.335

9.  Design, synthesis, and evaluation of 10-N-substituted acridones as novel chemosensitizers in Plasmodium falciparum.

Authors:  Jane X Kelly; Martin J Smilkstein; Roland A Cooper; Kristin D Lane; Robert A Johnson; Aaron Janowsky; Rozalia A Dodean; David J Hinrichs; Rolf Winter; Michael Riscoe
Journal:  Antimicrob Agents Chemother       Date:  2007-09-10       Impact factor: 5.191

10.  No seasonal accumulation of resistant P. falciparum when high-dose chloroquine is used.

Authors:  Johan Ursing; Poul-Erik Kofoed; Amabelia Rodrigues; Lars Rombo
Journal:  PLoS One       Date:  2009-08-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.